文献速递艾滋病与性传播感染

法国随访的HIV-1/O与HIV-1/M患者对cART免疫学和病毒学应答的比较

Comparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

在法国随访的未治疗HIV-1/O感染者与HIV-1/M感染者启动cART后,总体分析显示HIV-1/O组基线血浆病毒载量较低但基线CD4计数也较低,治疗4个月后CD4增幅无差异,4个月后HIV-1/O组CD4计数仍较低;当考虑患者流行病学特征后,两组免疫学和病毒学应答无差异。

要点

  • 总体人群中HIV-1/O组启动cART时血浆病毒载量较HIV-1/M组低0.6 log10 copies/mL(P=0.004)。
  • HIV-1/O组基线CD4计数中位数180/mm3,低于HIV-1/M组的248/mm3(P=0.001)。
  • 在2INTI+1PI/r方案人群中,HIV-1/O组基线病毒载量低1 log10 copies/mL,达到pVL<200 cp/mL更快(log rank检验P<0.001),免疫学应答相似。

核心结论

  • 当考虑患者流行病学特征后,HIV-1/O与HIV-1/M对cART的免疫学和病毒学应答无差异。
  • 在法国,按照HIV-1/M指南治疗HIV-1/O可获得相似的治疗结局。

研究设计与样本

  • 研究纳入ANRS-ORIVAO研究中在法国启动cART的未治疗HIV-1/O感染者,与ANRS-COPANA队列中启动cART的未治疗HIV-1/M感染者进行比较。
  • 总体分析纳入65例HIV-1/O与279例HIV-1/M,并另行分析启动2INTI+1PI/r方案的患者。
  • 采用分段线性混合效应模型和Kaplan-Meier生存曲线分析免疫学和病毒学应答。

主要发现

  • 总体人群中,HIV-1/O组启动治疗时血浆病毒载量较HIV-1/M组低0.6 log10 copies/mL(P=0.004),但启动cART后达到pVL<200 cp/mL的时间无差异(log rank检验P=0.57)。
  • HIV-1/O组基线CD4计数中位数180/mm3,低于HIV-1/M组的248/mm3(P=0.001)。
  • 治疗4个月时两组CD4计数增幅无差异(P=0.96),但治疗超过4个月后HIV-1/O组CD4计数仍较低(P=0.04)。
  • 在PI/r方案人群中,HIV-1/O组基线pVL较HIV-1/M组低1 log10 copies/mL,达到pVL<200 cp/mL显著更快(log rank检验P<0.001),免疫学应答相似。

临床怎么用

  • 在法国,按照HIV-1/M指南治疗HIV-1/O可获得相似的治疗结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapeutic outcomes for patients infected by genetically divergent HIV-1/O are not well-known due to scarce data and the lack of an appropriate comparison with patients infected by pandemic HIV-1/M. We aimed to compare the immunological and virological response to cART between HIV-1/O and HIV-1/M patients followed in France. METHODS: All naïve HIV-1/O subjects initiating cART in France in ANRS-ORIVAO study were compared to naïve HIV-1/M subjects initiating cART in ANRS-COPANA cohort. Piecewise linear mixed-effect models and Kaplan-Meier survival curves were used to analyse immunological and virological response to cART overall (65 HIV-1/O versus 279 HIV-1/M), then only in patients initiating 2INTI + 1PI/r. RESULTS: Plasma viral load (pVL) at treatment initiation was 0.6 log10 copies/mL lower in HIV-1/O than in HIV-1/M patients (P = 0.004) in the overall population, but there was no difference in the time to pVL < 200 cp/mL after cART initiation (log rank test, P = 0.57). Meanwhile, baseline CD4 counts were lower in HIV-1/O (median 180/mm3) than HIV-1/M (248/mm3) patients (P = 0.001). At 4 months, the increase in CD4 counts did not differ (P = 0.96) between groups but remained lower in HIV-1/O patients beyond 4 months of treatment (P = 0.04).In PI/r population, baseline pVL was 1 log10 copies/mL lower for HIV-1/O than HIV-1/M patients, leading to significantly faster attainment of pVL < 200 cp/mL (log rank test: P < 0.001); immunological response to cART was similar. CONCLUSIONS: HIV-1/O and HIV-1/M immunological and virological responses to cART did not differ when epidemiological characteristics of the patients were taken into account. In France, treating HIV-1/O following HIV-1/M guidelines leads to similar therapeutic outcomes.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Unal G, Seng R, Alessandri-Gradt E, et al. Comparison of the immunological and virological responses to cART between HIV-1/O and HIV-1/M patients followed up in France. J Antimicrob Chemother. 2025. PMID: 39804210. doi:10.1093/jac/dkae475

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。